Background Dietary or supplementary intake of nutrients and other ingredients positively affects skin appearance. Aims Evaluate a multicomponent nutritional supplement on photoaged skin. Patients/Methods This multicenter, double-blind, placebo-controlled trial randomized healthy 35-to 65-year-old women with Fitzpatrick skin types I-IV and Glogau classification types II-III to a multicomponent nutritional supplement or placebo for 24 weeks. The primary endpoint was Investigator Global Assessment of overall facial appearance at week 24. Secondary endpoints included investigator-and subject-rated assessments of the face, d ecolletage, and hands; facial photography assessments (conducted by an independent panel of dermatologists); and instrumental measures. Analysis of variance was used to assess between-group differences (P ≤ 0.05). Results Of 194 randomized subjects, 171 completed the study. Subjects had a mean age of 53 years and were primarily white (81%), had Glogau II (58%) and Fitzpatrick III (45%; significantly more supplement subjects had Fitzpatrick III [54%] vs. placebo [35%]; P = 0.039). At week 24, Investigator Global Assessment of overall facial appearance was numerically but not statistically better for supplement over placebo (mean difference: 0.14 [95% confidence interval: À0.16-0.44]; P = 0.358). A significant treatment-by-site interaction (P = 0.073) was observed; by-site analyses revealed a significant difference at one of three geographical sites for supplement vs. placebo (P = 0.001). Differences on secondary endpoints were generally not significant. Conclusions In the first multicenter study conducted with this multicomponent nutritional supplement, no significantly greater effects vs. placebo were observed on the primary endpoint, perhaps because of significant between-site variability.
Introduction
Exposure to ultraviolet (UV) radiation is the primary extrinsic factor that drives skin aging, which leads to the development of fine lines, wrinkles, and discoloration. [1] [2] [3] [4] [5] Orally administered essential micronutrients, plant extracts, and marine-based components have been studied for their effects on photoaged skin. [5] [6] [7] [8] [9] Dietary intake of and supplementation with these nutrient and non-nutrient ingredients can positively affect the skin's appearance by providing photoprotection from UV radiation and reducing oxidative stress and inflammation. 10, 11 Marine-based products, in particular, have gained attention for their anti-aging effects on the skin. 12 The oral multicomponent nutritional supplement (MNS) that is assessed here is formulated with 210 mg of a proprietary marine complex, 48 mg of vitamin C, 3.6 mg of zinc, and 56 mg of a patented tomato and grape seed extract blend. In an in vitro model using human skin equivalents, this marine complex increased collagen and laminin deposition, suggesting a potential anti-aging benefit. 13 This MNS has been studied previously in two open-label, noncomparative trials 14, 15 and a randomized, controlled trial 16 conducted with populations of healthy women. In the open-label trials, significant improvements in investigator rating of facial appearance and other endpoints were observed compared with baseline. 14, 15 In the randomized, controlled trial, the MNS demonstrated significantly greater improvement as compared to placebo on investigator global assessment of overall facial appearance. 16 Controlled trials with other formulations that contain this marine complex and other antioxidants and plant extracts 17, 18 also demonstrated significant improvements compared with placebo on investigator global assessment of overall facial appearance and other skin aging parameters. The current randomized, doubleblind, placebo-controlled clinical trial is the first multicenter study conducted to assess the effects of the MNS for improving the appearance of photoaged skin in healthy women. A meta-analysis that included previous studies and the current study was performed to assess the totality of data from controlled clinical trials conducted with formulations that are related to the current MNS with regard to effects on investigator-rated overall facial appearance. Demonstrating the efficacy of the marketed dietary supplement formulations in multiple clinical trials, which is often lacking in this area of research, is important for informing consumers as well as for clinical decision making. 19 
Methods

Study design
This phase four, randomized, double-blind, placebocontrolled study was conducted at four study centers in the United States (referred to in the current report as sites A-D). Subjects were assessed over a 24-week treatment period, which was preceded by a 28-day washout. The study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines. Subjects were required to sign dated informed consent forms before any screening procedures were performed. The final protocol, any amendments, and informed consent forms were reviewed and approved by each center's Institutional Review Board.
Study treatment
Subjects were instructed to take two tablets per day of either the MNS (Imedeen Compliance with study procedures and materials was assessed at week 3 through telephone contact, as were changes in health status, occurrence of adverse events (AEs), and changes in medication and dietary supplement use. Noncompliant subjects were re-educated on the instructions for properly using study materials.
Inclusion criteria
Healthy adult females, 35-65 years of age, with a body mass index of 20-34 kg/m 2 , Fitzpatrick skin classification types I-IV, and Glogau facial photoaging classification of II or III were enrolled. Women of childbearing potential were required to use effective contraception throughout the study and for 28 days after the last dose of assigned study product. All subjects were required to be current users of facial moisturizers (5 or more days/week) and willing to replace their current products with the assigned products.
Throughout the washout and active treatment periods, subjects were required to utilize a standardized facial cleanser (Purpose â Liquid Cleansing Wash;
Valeant Consumer Products, Bridgewater, NJ, USA) and moisturizing lotion (Purpose Dual Treatment Moisturizing Lotion with SPF 15; Valeant Consumer Products) in place of their current facial care products to standardize basic skin care procedures between subjects.
Exclusion criteria
Subjects with histories of or current skin diseases or conditions deemed by the investigator to be inappropriate for study participation, including atopic skin, facial scarring, psoriasis, and eczema, were excluded. Diagnoses of medical or psychiatric disorders that could interfere with study participation or interpretation of results, impaired circulation, difficulty swallowing tablets, or a condition that could impact digestion and/ or absorption (other than mild acid reflux) were exclusionary. Subjects who currently smoked or had histories of smoking within 1 year of baseline; were currently pregnant or breast-feeding; had allergies or sensitivities to fish or soy; or had or were planning to have any facial cosmetic procedures, including injectable neurotoxins within 6 months of baseline, or other facial procedures (e.g., fillers, peels, dermabrasion, laser treatments) within 9 months of baseline were excluded.
Restricted concomitant treatments
Subjects were instructed to maintain their current dietary habits and body weight, to avoid excessive exposure to the sun and tanning beds, not to begin using new personal skin care products, and to maintain their current cosmetic product regimen. Subjects were restricted from using dietary supplements and over the counter or prescription products indicated for improving the appearance or condition of the skin within 1 month of baseline, but were permitted to continue using a daily multivitamin and/or a calcium supplement (≤1,200 mg daily) with vitamin D (≤1000 IU daily). Subjects were restricted from stopping or starting hormone therapy within 1 year of baseline, using prescription retinoids within 6 months of baseline, using other oral retinoids within 1 year of baseline, or using retinol or other nonprescription retinoids and alpha hydroxy acid-containing cosmetics.
Study procedures
During visit one, after providing informed consent, potential subjects underwent screening procedures, including baseline facial photography, eligibility assessments, Fitzpatrick and Glogau skin classification assessments, and vital sign and demographic assessments. Following confirmation of eligibility, including verification of photographic quality, subjects initiated the washout phase, stopped contraindicated dietary supplements and skin care treatments, and began using the assigned cleanser and moisturizer. The washout period also allowed for adjustment to the standardized facial care products. Upon completion of the washout, eligible subjects returned to the study site for baseline assessments and blinded randomization to the MNS or placebo at a one:one ratio as determined by a computer-generated randomization schedule. Subjects returned to the study site at weeks 6, 12, 18, and 24. The sponsor conducted routine site visits to review study procedures, compare data collection methods to original records, resolve potential data queries, and discuss protocol deviations. A routine quality assurance audit was performed at one site by the sponsor.
Outcomes
Investigator-rated assessments The primary efficacy endpoint was the Investigator Global Assessment (IGA) of subjects' overall facial appearance at week 24. Secondary investigator assessments included IGA of overall facial appearance at week 12, periocular and perioral fine lines and wrinkles, under-eye dark circles or bags, mottled hyperpigmentation (i.e., uneven, patchy, blotchy areas of light and dark and solar lentigines), sallowness/yellowing, and roughness/texture at weeks 12 and 24. D ecolletage and back of the hand crepyness and mottled hyperpigmentation were assessed at weeks 12 and 24. A scale of 0-9 was used to rate these outcomes: Mild: 0 to ≤3; moderate: >3 to ≤6; severe: >6 to ≤9; the use of half-points was encouraged as necessary (e.g., 0, 0.5, 1, 1.5).
To promote consistency among investigator assessments across clinical sites, reviewers were provided with a photonumeric scale ( Fig. 1 ) that was used as a visual aid to standardize ratings. Prior to the development of this scale, the study investigators attended a training meeting where they graded the live models that were ultimately used in the scale and compared their assessments to establish consensus between investigators. Based on these evaluations, the photonumeric scale was developed for use at each of the four study sites as a rating guide to reduce intrasite variability with respect to the IGA. The scale included a left oblique facial view of three subjects. To create a photonumeric scale with no individual facial anatomy characteristics that typically introduce noise into the grading procedure, a base image of each subject was modified using Adobe Photoshop (Adobe Systems Inc, San Jose, CA, USA) to simulate varying degrees of photoaging severity (i.e., dyschromia and fine wrinkles associated with each score). Efforts were made to ensure that the same evaluator conducted all assessments for a given subject throughout the study. The positioning of the face, d ecolletage, and hands was consistent at every visit, and assessments occurred in the same examination room to ensure consistent lighting conditions between assessments.
Standardized facial photography Standardized facial photography was conducted at baseline and weeks 12 and 24 using a Canfield VISIA-CR 2.2 (Canfield Scientific, Inc., Fairfield, NJ, USA) facial imaging booth with a Canon 5D digital camera body. Photographs were taken of the right and left sides of the face at oblique 45°angles and frontally at 0°with the subject's eyes closed, jewelry and makeup removed, and hair kept away from the face. Lighting, framing, exposure, and reproduction ratios were consistently maintained within the controlled VISIA-CR environment. Photographs were assessed for technical quality and adequacy, and reshoots were scheduled within 14 days if the quality of the photograph prevented accurate assessment of photoaging. Each imaging session included a sequence of images with six unique lighting capture methods: standard white light, standard diffuse light, cross-polarized, UV fluorescence, parallel polarized, and custom white light configured to highlight fine lines and wrinkles.
Independent dermatologist photographic assessments
Photographic assessments of overall facial appearance were conducted by an Independent Panel Review Committee (IPRC) composed of three independent board-certified dermatologists who were neither study investigators nor familiar with the study protocol and were blinded to the investigator's assessments. Reviewers assessed the same set of photographs for each subject blinded to time point and treatment in accordance with Canfield image review procedures. IPRC members made comparisons between subjects' baseline photographs and those taken at week 24 using a À3 to 3 improvement scale: À3: definite worsening; À2: moderate worsening; À1: slight worsening; 0: no change; 1: slight improvement; 2: moderate improvement; 3: definite improvement.
Subject-rated assessments
At baseline, subjects evaluated the degree of photoaging of their face, back of hands, d ecolletage, and overall body using a 1-10 scale. At the week 12 and 24 visits, subjects rated the degree of improvement or worsening from À3 to 3: À3: definite worsening; À2: moderate worsening; À1: slight worsening; 0: no change; 1: slight improvement; 2: moderate improvement; 3: definite improvement. The following parameters were assessed: overall facial appearance; fine lines/wrinkles in the eye area, upper lip, or cheeks; under-eye dark circles/bags; discoloration, complexion, and smoothness of facial skin; overall appearance, fine lines/wrinkles, and discoloration of the back of the hands and d ecolletage; and overall body dryness. If improvement was observed in body dryness, the subject was asked to specify the area where the improvement was observed.
Instrumental assessments
Instrumental assessments were conducted at weeks 6, 12, 18, and 24. Up to three corneometry measurements were taken on the left cheek and inner and outer arm utilizing DermaLab Combo SkinLab (Cortex Technology, Hadsund Denmark) with an eight-pin probe. Corneometry determines skin hydration, reported in arbitrary units. Three transepidermal water loss (TEWL) measurements were taken of the left cheek and inner and outer arm utilizing a DermaLab Combo SkinLab unit. TEWL is expressed as g/m 2 /h and measures the amount of water vapor moving across the stratum corneum to assess skin barrier integrity. Ultrasound measurements of skin thickness and density of the left cheek and inner and outer arm were conducted using the DUB Cutis (Taberna Pro Medicum GmbH, Lueneburg, Germany) ultrasound unit. Ultrasound images were evaluated by a blinded central reader to ensure quality and consistency. Data from images with poor or not acceptable quality as determined by the central reader were excluded from analysis. While the objective was to obtain skin density measurements using a calibration mode set to 160%, measurements from two sites included a calibration mode of 100%, and thus could not be unified in terms of a numerical scale. Therefore, the primary population for the ultrasound skin density measurements included only subjects whose ultrasound skin density measurements were performed with 100% calibration.
Safety/tolerability assessments AEs were identified by subject spontaneous reporting and direct questioning beginning with the first dose of study treatment until the last visit.
Statistical analyses
All statistical computations were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA). Statistically significant differences were defined as P ≤ 0.05 (two-sided). IGA of overall facial appearance, the primary efficacy variable, was analyzed using analysis of variance (ANOVA) with treatment, study site, Glogau classification, and baseline score in the model. Overall treatment effects were tested using the least squares means (LSMs) and standard errors when the final model was obtained. Changes from baseline on secondary endpoints were analyzed using ANOVA with treatment, study site, Glogau classification, and as appropriate, the corresponding baseline assessment, and, depending on the variable, the calibration mode, and image magnification classification. Categorical secondary endpoints were analyzed using the Cochran-Mantel-Haenszel test stratified by Glogau classification, study site, and, as appropriate, the corresponding baseline value for the parameter being analyzed, using modified ridit scores for ordered variables.
Interactions between treatment and study site and corresponding baseline value of the dependent variable (significance level: P ≤ 0.10) were assessed in separate models by adding each interaction term, one at a time, to the initial ANOVA model. Regardless of the treatmentby-site interaction being generally significant or nonsignificant across variables, this term was not added to the final model. If the treatment-by-correspondingbaseline values were statistically significant, it was retained in the final model. For categorical outcomes, interaction terms of treatment-by-site or treatment-by-baseline-value were computed using the pseudo-homogeneity test.
Approximately 80 subjects per group were predicted to provide ≥80% power to detect a difference of 0.25 units between the MNS and placebo groups for change from baseline to week 24 in IGA of overall facial appearance. Analyses were performed using the modified intention-to-treat population, defined as all randomized subjects who had one or more pre-and postdose assessment value. The ultrasound skin density analysis only included subjects with measurements performed with 100% calibration.
Meta-analysis
The objective of the meta-analysis was to obtain an overview of the efficacy of the MNS compared with placebo for improving the appearance of photoaged skin among healthy women, as measured by IGA of the subjects' overall facial appearance. All randomized, placebo-controlled studies that were conducted with formulations related to the current MNS and were ≥12 to 24 weeks in duration and rated IGA of overall facial appearance on a scale similar to the current study were included; three studies (C07- 16 ) met these criteria. The observed mean treatment differences, pooled standard deviations, and 95% CIs were calculated for all four studies using the final time point from each study. Of note, the IGA for the current study was derived after the last-observation-carried-forward method was applied to estimate missing data, whereas no rules for missing data were used in the previous studies (i.e., changes from baseline were calculated based on the data available for the time point analyzed). The meta-analysis of all studies was performed using a random effects model. The methodology of the previous studies, which were 12, 16, and 24 weeks in duration, was similar to the methods described for the current study.
16-18
Results
Subject disposition
Of the 194 enrolled subjects, 171 (MNS: 89 [90.8%]; placebo: 82 [85.4%]) completed the study (Fig. 2) . The most common reasons for discontinuation for both groups were no longer willing to participate (MNS: 4.1%; placebo: 3.1%), occurrence of AEs (MNS: 3.1%; placebo: 4.2%), and lost to follow-up (MNS: 2.0%; placebo: 3.1%).
As specified in the planned analyses, because of the low enrollment rate (seven subjects) at site B and its close geographic proximity to site D, the data from these sites were pooled. All statistical analyses of efficacy endpoints were adjusted with the geographically pooled site term instead of the individual sites.
Demographics
Subjects were primarily white (81.3%) and postmenopausal (59.1%), with an average age of 53 years (range: 37-65 years) and weight of 67.3 kg (range: 50-94 kg; Table 1 ). Subjects were divided relatively evenly among advanced (42.5%) and moderate (57.5%) Glogau classification, while subjects predominantly (44.6%) had Fitzpatrick skin type III. A significant difference (P = 0.039) was observed between groups on Fitzpatrick skin type classification; more subjects were rated as type III in the MNS group than in the placebo group. Analysis of baseline characteristics in the individual sites showed that the difference in Fitzpatrick skin type classification was predominantly attributable to a significant difference (P = 0.044) at one of the four study sites (site C). At this site, 59.4% of the MNS group had type III compared with 28.1% of the placebo group, while at the other sites, the distributions were 46-59% (MNS) and 35-42% (placebo). No other significant between-group differences were observed in the individual sites; however, notable differences across sites were observed in race and ethnicity. More than half (55%) of the study population was Hispanic/Latino at site C, whereas there was minimal or no Hispanic/Latino representation at the other sites (one subject at site A; zero subjects at sites B and D). The majority of subjects (176 [92.1%]) had a treatment compliance rate of 80-120%.
Investigator-rated assessments
The MNS was found to be numerically better than placebo on the IGA of overall facial appearance (LSM difference: 0.14; 95% confidence interval [CI]: À0.16, 0.44), but the difference was not significant (P = 0.358; Fig. 3a) . A significant treatment-by-site interaction (P = 0.073) was observed on this endpoint.
Due to the significant treatment-by-site interaction on the primary efficacy endpoint, efficacy parameters were examined by individual study site. Subgroup analysis by site of the IGA of overall facial appearance demonstrated a significant improvement (LSM difference: 0.67; 95% CI: 0.29, 1.05; P = 0.001) at one of the three geographical sites (site A). No significant differences on the primary endpoint were observed at the other sites, one of which (site C) had a range of scores (min, max: À1.0, 5.0) that was out of proportion with the other sites (min, max: À1.0, 2.0). The variability at this discrepant site (site C root-mean-square of errors [RMSE]: 1.403) was more than double what was observed at the other sites (RMSE: 0.655-0.686), indicating an inconsistency in rating. The majority of other investigator-rated assessments did not show between-group differences, but a number of outcomes tended to favor subjects who received the MNS compared with placebo (Fig. 3a) . *P values for race, ethnicity, Glogau classification of photoaging, Fitzpatrick skin classification, hormonal status, and number of years since last period are from the Cochran-Mantel-Haenszel test, controlling for Glogau classification of photoaging and site when appropriate; P values for age and weight are from analysis of variance model with treatment, Glogau classification of photoaging, and site terms. † Statistically significant at P ≤ 0.05. MNS, multicomponent nutritional supplement; SD, standard deviation. Face Figure 3 Least squares mean differences (95% CIs) from baseline to week 24. (a) Investigator-rated outcomes. (b) Subject-rated outcomes. CIs, confidence intervals; LL, lower limit of 95% CI; MNS, multicomponent nutritional supplement; UL, upper limit of 95% CI.
Photographic assessment
The results from the IPRC photographic assessment of subjects' overall facial appearance at week 24 showed no difference between the MNS and placebo (gamma: 0.037; 95% CI: À0.19, 0.27; P = 0.568). In both groups, more subjects were rated as having no change, yet a greater proportion of subjects experienced worsening with placebo (34.4%) compared with the MNS group (26.6%). No significant treatment-by-site interaction (P = 0.773) was observed for IPRC assessments of photographs, and no between-group differences were observed among the individual study sites.
Subject-rated assessments
Significant differences were not generally seen between the treatment groups on the subject-rated assessments; however, results on many outcomes favored subjects receiving the MNS compared with placebo (Fig. 3b) . A significantly greater degree of improvement in the overall appearance of the d ecolletage (gamma: 0.38; 95% CI: 0.23, 0.54; P = 0.017) was observed in the MNS group at week 12 but not week 24 (gamma: 0.21; 95% CI: 0.02, 0.39; P = 0.088).
Instrumental outcomes
A significant worsening in left cheek TEWL was observed with the MNS starting at week 12 (LSM difference: 1.10; 95% CI: 0.12, 2.09; P = 0.027) and extending to week 24 (LSM difference: 1.17; 95% CI: 0.20, 2.14; P = 0.019). No other notable changes were observed in any other instrumental outcome.
Safety analyses
A total of 178 AEs were reported by 86 subjects; three were rated as severe and not determined to be treatment related. Nine subjects experienced AEs that were treatment related (MNS: n = 5 [5.1%]; placebo: n = 4 [4.2%]) and primarily involved the gastrointestinal system. AEs that occurred in >5% of subjects were nasopharyngitis (MNS: 8.2%; placebo: 3.2%) and contact dermatitis (MNS: 5.1%; placebo: 0%).
Meta-analysis
The meta-analysis consisted of approximately 240-250 subjects in each treatment group. These studies enrolled a similar population to the current study; two studies enrolled approximately 40 subjects/group 16, 17 and one enrolled 70-80 subjects/group. 18 The women enrolled in these studies were approximately 50-57 years of age; one study 17 specifically enrolled postmenopausal women, so this population represents the upper limit of the age range. These studies also enrolled subjects based on Fitzpatrick and Glogau classification. The majority of subjects had Fitzpatrick skin type III, followed by type II. One study each also enrolled types I and IV, which represented a small proportion of the enrolled populations. Results of the pooled analysis of IGA of overall facial appearance data from the last time points of the current and prior studies conducted with different but related formulations of the MNS demonstrated an overall significant effect in favor of the MNS with ≥12 weeks' use of the product (Fig. 4) .
Discussion
The between-group differences in change from baseline in IGA of subject's overall facial appearance at week 24 (the primary endpoint for this study) did not reach statistical significance. Analysis of secondary endpoints revealed few significant differences: The MNS performed significantly better than placebo in reducing investigator-rated mottled pigmentation on the back of the hands at weeks 12 and 24 and subject-rated overall d ecolletage appearance at week 12, while some instrumental measures (e.g., TEWL in the left cheek) showed significant worsening in subjects taking the MNS. The clinical relevance of the latter finding is not clear, particularly in light of the fact that this population had healthy intact skin.
The results on the primary endpoint must be considered in light of the significant treatment-by-site interaction. When the sites were analyzed individually, significant improvement in IGA of overall facial appearance was observed at one site (site A), while there were no statistically significant differences between groups found at the other sites. Among the sites that failed to show a significant difference, the site with the smallest between-group differences for the MNS relative to placebo (site C) had more than double the variability in scores compared with the other sites, suggesting inconsistencies in rating at this site. Differences in the study population at baseline at this site, in which the majority of subjects were Hispanic with a greater proportion of Fitzpatrick skin type III, might have also contributed to the discrepant findings.
Results of the meta-analysis of all randomized, placebo-controlled trials with products related to the MNS provide level I evidence demonstrating positive effects on overall facial appearance based on investigator ratings when the product was used for ≥12 weeks. Other products formulated with similar ingredients have shown significant effects on some outcomes related to photoaging in randomized, placebo-controlled singlecenter trials. [20] [21] [22] These clinical trials generally did not prospectively identify a primary endpoint, however, which decreases the quality of the trials and strength of evidence.
Despite the lack of a significant treatment effect on the predefined primary endpoint, the methodology used in the current study could inform future research evaluating dietary supplements for treating photoaged skin. The study design had clear strengths, including aspects meant to control for potential confounding effects on skin appearance, such as the pretreatment washout period, use of standardized facial cleanser and moisturizer, and limits on supplement usages and sun/tanning bed exposure. Other strengths included specification of a predefined primary outcome measure, which is lacking in many clinical trials in this area, and utilization of a photonumeric scale to standardize investigator ratings. The significant variability across sites that was observed on the primary endpoint suggests that use of the photonumeric scale did not increase consistency in ratings as much as desired.
Importantly, this was the first multicenter study to be conducted with this MNS. This can strengthen generalizability of the findings by increasing the diversity of the study population. However, in this instance, the inclusion of multiple study sites also introduced significant variability, as indicated by the significant treatment-by-site interaction on the primary endpoint, which may have impacted the ability to detect a significant treatment effect. In addition to potentially increasing inter-rater variability, a multicenter trial can introduce geographic (particularly latitudinal 23 ) differences across the study sites that may be particularly relevant for photoaging outcomes such as facial appearance, where a small degree of change is expected and results may be subject to environmental factors. Although the 6-month duration of this study was thought to allow for sufficient time to observe the anticipated subtle changes in facial appearance, by performing baseline and endpoint assessments during different seasons, seasonal changes that occur in the skin throughout the year may have impacted the effects observed. Therefore, this study may have benefitted from a 12-month assessment period to allow baseline and endpoint assessments to be conducted in the same season.
Results for the instrumental outcomes included in the study were not helpful in detecting changes in 1.5 P = 0.001 P < 0.0001 P < 0.01 P < 0.01 P < 0.0001 Figure 4 Meta-analysis of observed mean differences (95% CIs) in Investigator Global Assessment of overall facial appearance across studies conducted with related MNS ≥12 weeks in duration. The P values for the current and previous studies are as per their respective study reports or publications. The P value for "All Studies" is derived from the random effects method employed in the meta-analysis. 95% LL, 95% confidence interval lower limit; 95% UL, 95% confidence interval upper limit; CIs, confidence intervals; MNS, multicomponent nutritional supplement.
this population. Although these measures are somewhat more objective than the purely subjective assessments conducted by investigators and subjects, they are also subject to variability as a function of the role of the investigator performing the assessments, primarily due to potential differences in probe placement and variability in subjectively rating the results. In contrast, assessments by the IPRC based on the standardized facial photography used in this study were more consistent across study sites. Subject assessments of improvement/worsening in photoaging parameters at postbaseline time points were contingent on the subjects' recollection of skin appearance at baseline. For some subject-rated assessments, significant differences were observed at 3 months but lost at 6 months. This may indicate diminished recollection at the later time point, suggesting the potential value of providing subjects in future studies of 6 months or longer with baseline photographs to aid in making comparisons of their appearance.
Conclusion
In this study, observed improvements with the MNS on overall facial appearance at 24 weeks (the primary endpoint) failed to reach statistical significance compared with placebo. A meta-analysis of placebocontrolled trials conducted with the MNS and other related formulations, representing the totality of level I evidence for this product, found significant differences supporting a beneficial effect of this MNS on investigator-assessed overall appearance of photoaged facial skin.
